BriaCell Therapeutics (TSX:BCT) Total Long-Term Liabilities : C$1.30 Mil (As of Jan. 2025)

View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. BriaCell Therapeutics's Total Long-Term Liabilities for the quarter that ended in Jan. 2025 was C$1.30 Mil.

BriaCell Therapeutics Total Long-Term Liabilities Historical Data

The historical data trend for BriaCell Therapeutics's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Total Long-Term Liabilities Chart

BriaCell Therapeutics Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Total Long-Term Liabilities

Get a 7-Day Free Trial

0.21

37.36

40.50

38.50

1.50

BriaCell Therapeutics Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Total Long-Term Liabilities	Get a 7-Day Free Trial															22.32	7.76	1.50	2.36	1.30

BriaCell Therapeutics Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

BriaCell Therapeutics Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

BCTX:USA 8BT0:Germany 8BT0:Germany

Address

235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Executives

Jamieson Bondarenko	Director
Marc Lustig	10% Security Holder, Director
Gadi Levin	Senior Officer
William Williams	Director, Senior Officer

BriaCell Therapeutics Headlines

No Headlines